Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights
Primary result · Change from baseline in SF-6D utility score, FASResult — go to the resultEstimated mean treatment difference 0.057 95% CI 0.038–0.076Authors' conclusion
To our knowledge, this is the first study showing statistically significant and clinically meaningful improvements in SF-6D utility scores with weight-loss pharmacotherapy in Australia.
Study context
- Population
- STEP 1 trial population (full analysis set (FAS)) and post-hoc subgroups by baseline body mass index (BMI) cut-off points and comorbidities
- Comparison
- Semaglutide 2.4 mg vs placebo
- Primary endpoint
- Change from baseline in SF-6D utility score (SF-36 mapped, Australian weights)
- Follow-up
- Week 68
Methodological detailspost-hoc subgroups, mixed model for repeated measurements
- Post-hoc subgroups
- Mixed model for repeated measurements
Primary result
Change from baseline in SF-6D utility score, FAS
Estimated mean treatment difference
0.057
95% CI 0.038–0.076
Semaglutide 2.4 mgvs Placebo
estimated mean treatment difference 0.057 (95% CI 0.038–0.076)
As reported in the abstract
Further findings
Change in SF-6D utility score, subgroups with symptomatic comorbidities · week 68
- Greater treatment effect; treatment difference range 0.077 (0.027-0.128) to 0.105 (0.030-0.179)
- 0.077 to 0.105
- Post-hoc subgroups
Baseline BMI and SF-6D utility, FAS
- Utility loss per 1-unit increase in BMI (adjusted for demographic and clinical parameters)
- 0.0075 (−0.0089 to −0.0062)
- Multiple linear regression
Original publication
Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights. Diabetes Obes Metab. Published 9 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →